Novel Antibody Therapeutics Congress
October 7, 2019
Location: London Heathrow Marriott Hotel, Bath Road, Harlington, Hayes, United Kingdom Dates: October 10-11, 2019 Booth: Ex-24 Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models Speaker: Benny Yang, Ph.D., Chief Scientific Officer & Director of Antibody Discovery, Biocytogen Time: Thursday, October 10th, 10:20-10:50am Presentation Abstract: Biocytogen […]
2nd Annual Advances in Immuno-Oncology USA Congress
October 2, 2019
Location: DoubleTree by Hilton Hotel San Diego, Mission Valley, USA Dates: October 8-9, 2019 Booth: #4 Presentation Title: Accelerating Therapeutic Antibody Discovery with Fully Human Antibody (RenMab™) Mice and Target Humanized Animal Models Speaker: Chaoshe Guo, Ph.D., M.D., Vice President & Global Head of Business Development of Biocytogen Time: Tuesday, Oct. 8th, 1:50-2:20pm Session: Translational […]
Experts in Genetically Engineered Animal Development and Maintenance
September 11, 2019
Time: 10:30-11:30am, Sept. 19th, 2019 Location: Conference Room D1, Building 114, Massachusetts General Hospital, 16th Street, Charlestown MA 02129 Speakers: Daniel Trombly, Ph.D. Gene Editing Specialist, Biocytogen Boston Corporation Christopher Dowdy, Ph.D. Client & Scientific Portfolio Manager Research Models and Services, Charles River Laboratories
2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress
August 30, 2019
Location: Hilton Garden Inn Philadelphia Center City Dates: Sept. 19-20, 2019 Booth: #Ex-7 Presentation Title: Accelerating Therapeutic Antibody Discovery and Development with Innovative Humanized Mouse Models Time: 10:05 AM, Sept. 19, 2019 Location: Stream B – Immune Checkpoint Inhibitors & Combination Strategies Presentation Abstract: The talk will present you Biocytogen services for your antibody discovery […]
Biocytogen Closes $79M Series D Funding
August 9, 2019
On August 2019, Beijing Biocytogen Co., Ltd. (“Biocytogen”) announced the closing of its Series D funding of $79M (RMB 543M). This round of financing was jointly led by investment giants China Life Healthcare Fund and SDIC Venture Capital Co., Ltd., and has demostrated continued participation from Series C investors CMB International and 3E Bioventures. Biocytogen […]
Biocytogen at the ESMO 2018 Annual Meeting
Biocytogen at the at the ESMO 2018 annual meeting, which will take place in Munich, Germany from between 19-23 October 2018.
American Association for Cancer Research (AACR) Annual Meeting 2019
Biocytogen Highlights 10 Posters highlight new IO targets (e.g. CTLA-4, OX40, CD3e), preclinical services, PK/PD studies, and antibody screening platform will be presented at AACR. Time Abstract Full Name Abstract # Board # Category Apr 1 8AM – 12PM Anti-SIRPα antibodies as a potential weapon for cancer immunotherapy via accelerated screening in humanized […]
Biocytogen seminar at the University of Western Ontario
Dr. James Jin, the Vice President of Biocytogen, will hold a seminar at the University of Western Ontario in London, Canada. This seminar mainly focuses on CRISPR/Cas9 based Extreme Genome Editing (EGE) Technology developed by Biocytogen and its Applications. The seminar is hosted by Dr. Cindy(Qing) Shao from the University of Western Ontario. Welcome to […]
Immuno-Oncology (IO) Summit 2018
August 4, 2018
Biocytogen attended Immuno-Oncology (IO) Summit 2018 congress in Boston, MA, Aug 28 – Aug 31. IO Summit has become the leading annual meeting focusing on the latest applied research. This conference covers immunomodulatory antibody engineering and emerging immuno-oncology targets, combination immunotherapy, preclinical and translational IO, predictive biomarkers and companion diagnostics, adoptive T cell therapy, oncolytic […]
